Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide

被引:11
|
作者
Boytsov, Natalie [1 ]
Zhang, Xiang [1 ]
Sugihara, Tomoko [2 ]
Taylor, Kathleen [1 ]
Swindle, Ralph [1 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] InVentiv Hlth Clin, Princeton, NJ USA
关键词
Comparative effectiveness; Healthcare resource utilization; Osteoporosis; Teriparatide; BONE-MINERAL DENSITY; PERSISTENCE; ADHERENCE; SCORE;
D O I
10.1185/03007995.2015.1066765
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To compare fractures and fracture-related resource utilization (RU) among patients with a recent fracture and treated with teriparatide (TPTD) to a matched cohort of patients not treated with TPTD (non-TPTD). Research design and methods: Women aged 50 years or older initiating TPTD (N = 5314; index date between 1 January 2007 and 31 December 2012) were identified in an insurance claims database. Patients with fragility fracture (hip, pelvis, clavicle, humerus, wrist, leg or spine) during the 12 months prior to the index date (N = 1164) were selected to control for unmeasured confounding due to absence of bone mineral density test levels. TPTD patients were matched to the non-TPTD cohort using propensity score and exact matching (N = 912). Relative risk (RR) of fracture and fracture-related RU were estimated by Cox proportional hazard modeling, adjusted for potential fracture risk factors. Results: Fractures were observed in 4.6%, 8.6%, 10.3%, and 11.3% of TPTD patients and in 9.2%, 15.2%, 19.2% and 21.7% of non-TPTD patients over 6, 12, 18, and 24 months, respectively. The adjusted RR reduction in TPTD was 36% (RR = 0.64, 95% CI: 0.44-0.94) during 6 months, 27% (RR = 0.73, 95% CI: 0.54-0.97) during 12 months, 28% (RR = 0.72, 95% CI: 0.55-0.93) during 18 months, and 28% (RR = 0.72, 95% CI: 0.56-0.92) during 24 months versus matched non-TPTD patients. Fracture-related RU followed a similar trend to that observed for fracture risk. Conclusions: This real-world study found TPTD to be more effective in reducing risk of fragility fractures as early as 6 months with continuous treatment benefit up to 24 months compared to a matched non-TPTD cohort. TPTD patients experienced lower rates of fracture-related RU than non-TPTD patients. Key study limitations include the inability to confirm reported diagnostic and procedural codes and the absence of uninsured and individually insured patients in the claims database.
引用
收藏
页码:1665 / 1675
页数:11
相关论文
共 50 条
  • [31] BMD response to Teriparatide in treatment naive patients versus patients previously treated with a bisphosphonate
    File, E. A.
    Deal, C. L.
    Butler, R. S.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S323 - S323
  • [32] COST REDUCTION AND BURDEN OF DISEASE IN TERIPARATIDE-TREATED PATIENTS WITH OSTEOPOROSIS AND PREVIOUS FRACTURES: A PAYER'S PERSPECTIVE
    Akarirmak, U.
    Emral, R.
    Gumusel, B.
    Ketenci, A.
    Sindel, D.
    Tokgozoglu, A. M.
    Tuzun, S.
    Yavuz, D. G.
    Ertekin, A.
    Gurbuz, S.
    Koral, S.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A239 - A240
  • [33] Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study
    Beall, D. P.
    Feldman, R. G.
    Gordon, M. L.
    Gruber, B. L.
    Lane, J. M.
    Valenzuela, G.
    Yim, D.
    Alam, J.
    Krege, J. H.
    Krohn, K.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2016, 27 (03) : 1191 - 1198
  • [34] Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study
    D. P. Beall
    R. G. Feldman
    M. L. Gordon
    B. L. Gruber
    J. M. Lane
    G. Valenzuela
    D. Yim
    J. Alam
    J. H. Krege
    K. Krohn
    [J]. Osteoporosis International, 2016, 27 : 1191 - 1198
  • [35] The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures
    Hadji, P.
    Zanchetta, J. R.
    Russo, L.
    Recknor, C. P.
    Saag, K. G.
    McKiernan, F. E.
    Silverman, S. L.
    Alam, J.
    Burge, R. T.
    Krege, J. H.
    Lakshmanan, M. C.
    Masica, D. N.
    Mitlak, B. H.
    Stock, J. L.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2012, 23 (08) : 2141 - 2150
  • [36] Evidence for Use of Teriparatide in Spinal Fusion Surgery in Osteoporotic Patients
    Chaudhary, Navjot
    Lee, Jennifer S.
    Wu, Joy Y.
    Tharin, Suzanne
    [J]. WORLD NEUROSURGERY, 2017, 100 : 551 - 556
  • [37] Worsening of calcinosis cutis with teriparatide treatment in two osteoporotic patients
    Echeverri, A. F.
    Ospina, F. E.
    Canas, C. A.
    Agualimpia, A.
    Suso, J. P.
    Tobon, G. J.
    Bonilla-Abadia, F.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (05) : 1049 - 1051
  • [38] The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures
    P. Hadji
    J. R. Zanchetta
    L. Russo
    C. P. Recknor
    K. G. Saag
    F. E. McKiernan
    S. L. Silverman
    J. Alam
    R. T. Burge
    J. H. Krege
    M. C. Lakshmanan
    D. N. Masica
    B. H. Mitlak
    J. L. Stock
    [J]. Osteoporosis International, 2012, 23 : 2141 - 2150
  • [39] BONE EVOLUTION IN PATIENTS TREATED WITH TERIPARATIDE DUE TO OSTEOPOROSIS: NEW RISK OF FRACTURE
    Pons, J.
    Ilundain, A. I.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S309 - S309
  • [40] TRABECULAR BONE SCORE IN PATIENTS WITH CHRONIC GLUCOCORTICOID OSTEOPOROSIS TREATED WITH ALENDRONATE OR TERIPARATIDE
    Saag, K. G.
    Agnusdei, D.
    Hans, D.
    Kohlmeier, L. A.
    Krohn, K. D.
    Leib, E. S.
    Maclaughlin, E. J.
    See, K.
    Simonelli, C.
    Taylor, K. A.
    Marcus, R.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S84 - S85